Wire Stories

Category Added in a WPeMatico Campaign

Seagen_Logo_RGB

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab...

AnHeart_Logo_2_28129_28129

AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

NEW YORK & SEOUL, South Korea--(BUSINESS WIRE)--#BTD--AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that...

Cellusion_logo_high_below10M

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region

Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights....